TNFRSF10B and prostate carcinoma: Artepillin C restores TRAIL sensitivity in TRAIL-resistant LNCaP prostate cancer cells by upregulation of TRAIL-R2, activation of caspase-8 and caspase-3, as well as the disruption of MMP [68].